Tumor regression (>25% reduction in tumor volume) was seen in 163 of 183 (89%) of tumors treated with abemaciclib monotherapy, simulating the regressions seen with CDK4/6i monotherapy in patients (Supplementary Fig. S10A; refs. 34, 35). Here, CDK4 is linked to neoplasm.